<DOC>
	<DOCNO>NCT00900614</DOCNO>
	<brief_summary>The purpose study determine high feasible dose ( HFD ) intravenous ( IV ) APR-246 give patient refractory hematologic malignancy prostate carcinoma .</brief_summary>
	<brief_title>Safety Study APR-246 Patients With Refractory Hematologic Cancer Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Summary criterion participant selection : Male female â‰¥ 18 year age . Any mention advanced disease , eligible therapy . The diagnosis confirm either histologically cytologically : 1 . Acute myeloid leukemia . 2 . Acute lymphoid leukemia . 3 . Chronic lymphocytic leukemia . 4 . Chronic myeloid leukemia . 5 . Chronic myelomonocytic leukemia . 6 . Multiple myeloma . 7 . Non Hodgkin 's lymphoma . 8 . Hodgkin 's lymphoma . 9 . Myelodysplastic syndrome . 10 . Myelofibrosis . 11 . Hormone refractory , metastatic prostate carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Hematologic malignancy</keyword>
	<keyword>Prostate carcinoma</keyword>
	<keyword>Hematologic cancer</keyword>
	<keyword>Prostate cancer</keyword>
</DOC>